文献速递呼吸衰竭与机械通气

ROX指数预测新发急性呼吸衰竭患者无创通气失败

Prediction of noninvasive ventilation failure using the ROX index in patients with de novo acute respiratory failure.
PubMed 文献 · Ann Intensive Care · 2022-12-05
一句话结论多中心前瞻性队列二次分析显示,ROX指数对新发急性呼吸衰竭患者NIV失败的预测能力中等,24小时AUC升至0.77。

本研究为多中心前瞻性观察研究的二次分析,纳入1286例新发急性呼吸衰竭患者(排除高碳酸血症),计算NIV前及NIV后1-2、12、24小时的ROX指数。568例(44%)发生NIV失败,失败者ROX指数低于成功者。NIV前ROX≤2、2-4、4-6、6-8、8-10、>10组NIV失败率分别为92.3%、70.5%、55.3%、41.1%、35.1%、29.5%。ROX预测NIV失败的AUC从NIV前的0.64(95%CI 0.61-0.67)升至1-2小时的0.71(95%CI 0.68-0.74)、12小时的0.74(0.71-0.77)、24小时的0.77(0.74-0.80)。ROX指数与PaO2/FiO2预测能力相似,与PaO2/FiO2/呼吸频率除1-2小时时间点外无差异。

要点

  • NIV前ROX≤2组NIV失败率92.3%,2-4组70.5%,4-6组55.3%,6-8组41.1%,8-10组35.1%,>10组29.5%。
  • ROX预测NIV失败的AUC:NIV前0.64(95%CI 0.61-0.67),1-2小时0.71(95%CI 0.68-0.74),12小时0.74(0.71-0.77),24小时0.77(0.74-0.80)。
  • NIV失败患者ROX指数低于NIV成功患者,NIV后1-2、12、24小时评估也得到相似结果。
  • ROX指数与PaO2/FiO2预测NIV失败能力相似;与PaO2/FiO2/呼吸频率除1-2小时时间点外无差异。
  • 作者结论:ROX指数对新发急性呼吸衰竭患者NIV失败的预测能力中等。

适用人群与场景

  • 新发急性呼吸衰竭患者,排除高碳酸血症患者。

研究设计与关键结果

  • 研究类型:多中心前瞻性观察研究的二次分析,旨在更新风险评分;共纳入1286例新发急性呼吸衰竭患者,568例(44%)发生NIV失败。
  • NIV失败患者ROX指数低于NIV成功患者;NIV前ROX≤2、2-4、4-6、6-8、8-10、>10组NIV失败率分别为92.3%、70.5%、55.3%、41.1%、35.1%、29.5%,NIV后1-2、12、24小时评估结果相似。
  • ROX预测NIV失败的AUC:NIV前0.64(95%CI 0.61-0.67),NIV后1-2小时0.71(95%CI 0.68-0.74),12小时0.74(0.71-0.77),24小时0.77(0.74-0.80)。
  • ROX指数与PaO2/FiO2预测NIV失败能力相似;ROX指数与PaO2/FiO2/呼吸频率除1-2小时时间点外无差异。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察性研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ROX指数对新发急性呼吸衰竭患者NIV失败的预测能力中等,可用于辅助评估NIV失败风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The ratio of SpO2/FiO2 to respiratory rate (ROX) index is commonly used to predict the failure of high-flow nasal cannula. However, its predictive power for noninvasive ventilation (NIV) failure is unclear.

METHODS: This was a secondary analysis of a multicenter prospective observational study, intended to update risk scoring. Patients with de novo acute respiratory failure were enrolled, but hypercapnic patients were excluded. The ROX index was calculated before treatment and after 1-2, 12, and 24 h NIV. Differences in predictive power for NIV failure using the ROX index, PaO2/FiO2, and PaO2/FiO2/respiratory rate were tested.

RESULTS: A total of 1286 patients with de novo acute respiratory failure were enrolled. Of these, 568 (44%) experienced NIV failure. Patients with NIV failure had a lower ROX index than those with NIV success. The rates of NIV failure were 92.3%, 70.5%, 55.3%, 41.1%, 35.1%, and 29.5% in patients with ROX index values calculated before NIV of ≤ 2, 2-4, 4-6, 6-8, 8-10, and > 10, respectively. Similar results were found when the ROX index was assessed after 1-2, 12, and 24 h NIV. The area under the receiver operating characteristics curve was 0.64 (95% CI 0.61-0.67) when the ROX index was used to predict NIV failure before NIV. It increased to 0.71 (95% CI 0.68-0.74), 0.74 (0.71-0.77), and 0.77 (0.74-0.80) after 1-2, 12, and 24 h NIV, respectively. The predictive power for NIV failure was similar for the ROX index and for the PaO2/FiO2. Likewise, no difference was found between the ROX index and the PaO2/FiO2/respiratory rate, except at the time point of 1-2 h NIV.

CONCLUSIONS: The ROX index has moderate predictive power for NIV failure in patients with de novo acute respiratory failure.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Duan J, Yang J, Jiang L, et al. Prediction of noninvasive ventilation failure using the ROX index in patients with de novo acute respiratory failure. Ann Intensive Care. 2022. PMID: 36469159. doi:10.1186/s13613-022-01085-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。